OCA
DYN icon

Octagon Capital Advisors’s Dyne Therapeutics DYN Stock Holding History

Octagon Capital Advisors’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-668,000
Closed -$15.7M – 37
2024
Q4 		$15.7M Buy
668,000
+405,274
+154% +$12M 2.59% 16
2024
Q3 		$9.44M Sell
262,726
-918,072
-78% -$36.5M 1.47% 18
2024
Q2 		$41.7M Sell
1,180,798
-62,147
-5% -$1.81M 6.55% 5
2024
Q1 		$35.3M Buy
1,242,945
+450,000
+57% +$10.2M 4.23% 5
2023
Q4 		$10.5M Buy
792,945
+100,000
+14% +$977K 1.69% 15
2023
Q3 		$6.21M Hold
692,945
– – 0.95% 23
2023
Q2 		$7.8M Hold
692,945
– – 1.08% 17
2023
Q1 		$7.98M Buy
+692,945
New +$9M 1.15% 18
2022
Q2 		– Sell
-525,284
Closed -$5.06M – 22
2022
Q1 		$5.06M Sell
525,284
-58,365
-10% -$497K 1.09% 19
2021
Q4 		$6.94M Hold
583,649
– – 1.35% 17
2021
Q3 		$9.48M Hold
583,649
– – 2.33% 14
2021
Q2 		$12.3M Hold
583,649
– – 2.54% 12
2021
Q1 		$9.06M Buy
583,649
+102,111
+21% +$1.98M 3.41% 12
2020
Q4 		$10.1M Buy
+481,538
New +$9.52M 3.51% 13

Other funds holding DYN

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Octagon Capital Advisors's DYN Position: Q1 2025 in Review

Octagon Capital Advisors sold out of Dyne Therapeutics (DYN) in Q1 2025, closing a stake of 668,000 shares — an estimated $15.7M sold.

Octagon Capital Advisors first reported a position in DYN in Q4 2020 and held it in 14 quarters. The position peaked at $41.7M in Q2 2024. 205 funds tracked by Wall St. Rank hold DYN as of Q1 2025.

  • Octagon Capital Advisors reported no remaining Dyne Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Octagon Capital Advisors sold 668,000 Dyne Therapeutics shares in Q1 2025, an estimated $15.7M.
  • Octagon Capital Advisors first reported a position in Dyne Therapeutics in Q4 2020 and held it in 14 quarters.
  • Octagon Capital Advisors's Dyne Therapeutics position peaked at $41.7M in Q2 2024.
  • 205 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2025.

Based on Octagon Capital Advisors's 13F filing for Q1 2025, filed 15 May 2025.